Safety and tolerability of the treatment of youth-onset type 2 diabetes: The TODAY experience

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1765-1771

  White, Neil H ^a   Pyle, Laura ^b   Willi, Steven M ^c   Pham, Trang ^b   Chernausek, Steven D ^d   Goland, Robin ^e   Hale, Daniel E ^f   Haymond, Morey W ^g   Nadeau, Kristen J ^h   Narasimhan, Sumana ⁱ  

^a WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CONGENITAL MALFORMATION; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; WEIGHT GAIN;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; THIAZOLES;

EID: 84878254497     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2390     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of health and Human Services, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/ diabetes/pubs/pdf/ndfs-2011.pdf. Accessed 18 October 2012
2. Liese AD, D 'Agostino RB Jr, Hamman RF, et al.; SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006;118:1510-1518
3. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000;136:664-672 (Pubitemid 30318399)
4. Zeitler P, Epstein L, Grey M, et al.; TODAY Study Group. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8:74-87
5. Copeland KC, Zeitler P, Geffner M, et al.; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96:159-167
6. Zeitler P, Hirst K, Pyle L, et al.; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl JMed 2012;366:2247-2256
7. TODAY Study Group. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes (Lond) 2010;34:217-226
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28(Suppl. 1):S37-S42
9. Kahn SE, Zinman B, Lachin JM, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851
10. de Jager J, Kooy A, Lehert P, et al. Long term treatment withmetformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340:c2181
11. 12 supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2012;35:327-333
12. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94 (Pubitemid 41070789)
13. DeFronzo RA, Goodman AM; The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-549
14. Yki-Järvinen H. Thiazolidinediones.N Engl J Med 2004;351:1106-1118
15. Khanolkar MP, Morris RHK, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus dan effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008;197:718-724 (Pubitemid 351417869)
16. Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;67:43-52 (Pubitemid 40037729)
17. Berberoglu Z, Yazici AC, Bayraktar N, Demirag NG. Rosiglitazone decreases fasting plasma peptide YY3-36 in type 2 diabetic women: a possible role in weight gain? Acta Diabetol 2012;49(Suppl. 1): S115-S122
18. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263 (Pubitemid 38196741)
19. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967 (Pubitemid 36733754)
20. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-1393 (Pubitemid 46393782)
21. Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr 2005;41:94-98 (Pubitemid 40967362)
22. Wicklow BA, Wittmeier KD, MacIntosh AC, et al. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 2012;35:905-910
23. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757
24. Yki-Järvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009;20:477-483
25. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012;35:1265-1271
26. Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC. Incidence of retinopathy and nephropathy in youthonset compared with adult-onset type 2 diabetes. Diabetes Care 2003;26:76-81 (Pubitemid 36928997)
27. Balsells M, García-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab 2009;94:4284-4291
28. Levitt Katz LE, Swami S, Abraham M, et al. Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes 2005;6:84-89 (Pubitemid 40916641)
29. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-1201